U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07823764) titled 'Study of CM583 in Healthy Participants' on Sept. 08.
Brief Summary: This is a randomized, double-blind, placebo-controlled, single-ascending-dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM583 in healthy adult participants. Approximately 40 participants will be enrolled in five dose cohorts. Within each cohort, participants will be randomized in a 3:1 ratio to receive a single subcutaneous dose of CM583 or placebo.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
BIOLOGICAL: CM583
CM583 injection administered SC(Subcu...